NLS Pharma Stock Gains After Issuance Of Mazindol Patent

NLS Pharmaceutics Ltd NLSP has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/083,131.
Related: NLS Pharma's Narcolepsy Candidate To Enter Mid-Stage Study Next Month.
The patent covers oral formulations containing immediate-release and sustained-release layers of mazindol and their use in the treatment of attention deficit disorders, related deficit of alertness or decline in vigilance, or excessive daytime sleepiness.
The patent, which is expected to be issued in Q4 of 2021, will have a term that expires no earlier than March 2037.
Related content: Benzinga's Full FDA Calendar
NLS Pharma CEO told Benzinga that the company is on track to initiate the prospective Phase 2 clinical study for Quilience.
Price Action: NLSP shares are up 12.30% at $2.64 during the market session on the last check Thursday.